NEUPRO DIN 02403919
Health Canada record
| Active ingredient(s) | ROTIGOTINE 3 MG |
|---|---|
| Dosage form | Patch |
| Route | Transdermal |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N04BC09 ROTIGOTINE |
| Original market date | 19-Dec-2013 |
| Current status date | 19-Dec-2013 |
| Source | Health Canada DPD |
Establishment licence of the holder
UCB Canada Inc — licence 101597, currently licensed, last inspection rating C (2024-11-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ROTIGOTINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02403897 | NEUPRO | UCB CANADA INC | Patch | ROTIGOTINE 1 MG | Marketed |
| 02403900 | NEUPRO | UCB CANADA INC | Patch | ROTIGOTINE 2 MG | Marketed |
| 02403927 | NEUPRO | UCB CANADA INC | Patch | ROTIGOTINE 4 MG | Marketed |
| 02403935 | NEUPRO | UCB CANADA INC | Patch | ROTIGOTINE 6 MG | Marketed |
| 02403943 | NEUPRO | UCB CANADA INC | Patch | ROTIGOTINE 8 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14234 | 2013-03-21 | New Drug Submission (NDS) |
International API supply for ROTIGOTINE
4 valid EDQM Certificates of Suitability from 4 holders. 8 active FDA Drug Master Files.
Request a quote for NEUPRO